Bavarian Nordic wins freeze-dried Imvamune contract from US government

Published: 20-Nov-2009

The Biomedical Advanced Research and Development Authority (BARDA) in the US has awarded a US$40m contract to Bavarian Nordic of Denmark to develop a freeze-dried version of its Imvamune smallpox vaccine.


The Biomedical Advanced Research and Development Authority (BARDA) in the US has awarded a US$40m contract to Bavarian Nordic of Denmark to develop a freeze-dried version of its Imvamune smallpox vaccine.

The funds will be used to validate the freeze-dried manufacturing process and the associated pre-clinical and clinical studies to support the development of this version of the vaccine. The funding represents 33% of the total contract value, followed by four additional years of optional funding, which will be triggered by the completion of pre-determined technical milestones.

The freeze-dried development activities will be performed in parallel to the licensure activities of the current liquid-frozen Imvamune formulation under the existing RFP-3 contract.

With the new contract, the US Government has to-date awarded Bavarian Nordic more than US$680m for the development of Imvamune in liquid-frozen and freeze-dried formulations.

Bavarian Nordic says the freeze-dried version offers a potential increased shelf-life compared with the liquid-frozen formulation.

You may also like